SHARE:  
Join Our Email List
COVID-19 Review 2021/22
Relevant Information From Reviewing Various Sources
During this holiday break from the office we appear to be experiencing the highest rate of confirmed COVID infections since the "birth" of this new strain. I wanted to follow-up my Holiday Wishes announcement with some updated reviews. I would remind readers that colored font usually indicates there is a link action option to get more information. Let's start with the link that takes us to the a world map/information. Hover over World Covid-19 below and click it to see.
Pulled- Monoclonal Antibody Therapy for COVID-19
As you know, I have been reassuring our patients that we had Regen-Cov monoclonal antibody for injection or infusion available in our treatment algorithm. This is no longer the case. We have only a handful of treatments still in our inventory.

Last week the governing bodies pulled these options from the supply chain. They claimed (with literally no scientific evidence provided) that this would not work for the new Omicron strain. Further, the CDC initially reported that 80% or more of the infections were Omicron. By this past Monday, the CDC then admitted these reported facts weren't correct. Up to December 15th the majority of COVID samples genetically analyzed were still Delta in the US. To my understanding, they have not reversed the premature decision to withdraw this life-saving and game changing treatment option from the public.

I would encourage everyone to contact the NIH, FDA, CDC, and our President to request they re-allow monoclonal passive immunity therapies to be returned into the supply chain. Clinically, I have provided three doses this past week with very rapid patient improvement.
coronavirus COVID-19 microscopic virus corona virus disease 3d illustration
Covid- 19 Vaccination Effectiveness Study
Coronavirus Corona virus concept. USA wall breaking- business or economy fall for corona virus. Coronavirus outbreak on America and corona viruses influenza background. USA recession record.
A November 4th article published in the Journal of American Medicine provided some clarity regarding the observed facts for hospitalization and vaccination status. There are several interesting observations.
  • This was a 21 hospital sites, United States data set.
  • They looked at hospitalizations from March 11-August 15, 2021. This means part of the observation period included the transition to the Delta variant outbreak.
  • Being fully vaccinated (having 2 injections of either the Moderna or Pfizer vaccines, 2 weeks apart and 2 weeks past second injection) offered 85% reduced odds of hospitalization over unvaccinated persons.
  • If hospitalized and fully vaccinated, the odds of ventilation or death were about twice better than unvaccinated (12% vs 24.7%).
  • After 120 days, the Moderna Vaccine offered better protection than Pfizer.
  • Immunocompromised individuals had a much higher odds of failure for protection than normal immune status. Still there was a benefit.
  • Persons who had only one vaccine, a vaccine other than Moderna or Pfizer or a mixed vaccine schedule were NOT included in this observational data set. This amounted to excluding 966 of 5479 patients admitted. Of the 4513 enrolled for observation there were 2530 non COVID (test negative and syndrome negative) control participants. We can't conclude the level of protection in persons with one shot, other COVID vaccine or mixed vaccine status.



I would point out that for the purposes of protecting people from infections and observed case rates in the northern hemisphere (especially as more time elapses), the mRNA vaccines have not been meaningfully effective. We normally measure vaccine success by prevention of illness. COVID-19 has us now digging under the rubble to look for other positive outcomes, such as reported above. The prior world statistics link illustrates some very strange information. The US, UK, Russia and Northern Europe have the worse infection rates of all other countries despite all attempts to avoid infection. This leads me to explore what besides geography and race might explain these facts. As mortality data appears to be improving one has to wonder besides herd immunity developing, perhaps outpatient interventions are making a difference. See the Honduras news in the next section.
Honduras Experience
I think this interview makes an incredibly strong statement about the benefit of early diagnosis and management of COVID-19. This is a lengthy interview and it starts slow. You can move ahead to about 30 minutes in to get the real meat and potatoes.


Basically Dr. Fernando and his team using early intervention and stepped approach treatment for COVID turned a 17% mortality for ICU admissions from COVID to being a predominantly outpatient management condition with nil mortality.

Important points which I am coming out as learning and observing as well include:
  • Mitigating viral load can diminish severity of illness. Sinus and oral rinsing, use of controversial antiviral medications and identifying and sidelining infected persons helps.
  • Managing inflammation (which means symptoms like malaise, fever, histamine release) greatly improves how a patient will do.
  • After the first 7-10 days patients and doctors need to be watching out for an overactive immune response to the infection. This is host and viral load/duration correlated. Going backwards in symptoms especially breathing warrants aggressive anti- inflammatory/immune modulating therapy.
  • Addressing clotting and lung inflammation that can result from the immune response is key to changing mortality of the severely ill COVID patient.


Data that is presented in the interview can be found in the articles below (click to see).
Honduras Covid Treatment
Dr. Kordonowy is Invited To Regional Meeting as Panelist
As my experience in medicine continues, I have learned that the AAPS is the true physician and patient lobby. They defend the patient physician relationship and the noble profession of medicine unabashedly. I am happy to be sitting as a panelist discussant for early COVID-19 treatment. I would welcome anyone interested to attend. The event is in Sarasota February 11th.
Dr. Marconi's Joins us February 15th.
I have sent an E-blast to present patients introducing Dr. Marconi. We are very excited to have him join IMLWP. We are making more clinical space so pardon our dust. He will have an open schedule M- Friday beginning February 15th, 2022.
Internal Medicine Lipid & Wellness |http://www.imlwp.com/